Other bacterial pneumonia
ICD-10 J15.6; J15.8; J15.9 · ICD-11 CA40.0Z

Treatment of Other Bacterial Pneumonia in Community-Acquired Pneumonia with Pseudomonas aeruginosa Risk

Adult inpatients admitted with community-acquired pneumonia (CAP) who carry specific risk factors for Pseudomonas aeruginosa require a modified empiric antibiotic strategy — one that goes beyond the standard CAP approach to address this pathogen.

Clinical Scenario

This protocol applies to adult inpatients with community-acquired pneumonia who have at least one of the following risk factors for Pseudomonas aeruginosa:

Empiric coverage for P. aeruginosa is warranted only when locally validated risk factors such as these are present.

Treatment Approach

The regimen augments a standard CAP backbone with empiric anti-pseudomonal coverage — drawn from anti-pseudomonal beta-lactam agents combined with a macrolide or respiratory fluoroquinolone — alongside cultures obtained from the outset to enable deescalation. The complete agent selection and duration algorithm is available in the full protocol.

Clinical Goals

The protocol targets clinical improvement at 48 hours, with negative cultures permitting deescalation to standard CAP therapy. Full clinical stability — resolution of vital sign abnormalities, ability to eat, and normal mentation — is the benchmark that guides antibiotic duration, with a minimum course specified for confirmed or suspected cases.

Instant Access to Structured Evidence-Based Regimens

References

  1. We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present (strong recommendation, moderate quality of evidence).
  2. The most consistently strong individual risk factors for respiratory infection with MRSA or P. aeruginosa are prior isolation of these organisms, especially from the respiratory tract, and/or recent hospitalization and exposure to parenteral antibiotics.
  3. Empiric treatment options for P. aeruginosa include piperacillin-tazobactam (4.5 g every 6 h), cefepime (2 g every 8 h), ceftazidime (2 g every 8 h), aztreonam (2 g every 8 h), meropenem (1 g every 8 h), or imipenem (500 mg every 6 h).
  4. The duration of therapy for CAP due to suspected or proven MRSA or P. aeruginosa should be 7 days, in agreement with the recent hospital-acquired pneumonia and ventilator-associated pneumonia guidelines.
  5. Routine cultures in patients empirically treated for MRSA or P. aeruginosa allow deescalation to standard CAP therapy if cultures do not reveal a drug-resistant pathogen and the patient is clinically improving at 48 hours.
  6. We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).

DOI: 10.1164/rccm.201908-1581ST

View source ↗